Yaron Shargall, Emily T Vella, Maria Elisabeth Del Giudice, Carole Dennie, Peter M Ellis, Swati Kulkarni, Robert MacRae, Yee C Ung
{"title":"肺癌治愈患者随访的系统评价。","authors":"Yaron Shargall, Emily T Vella, Maria Elisabeth Del Giudice, Carole Dennie, Peter M Ellis, Swati Kulkarni, Robert MacRae, Yee C Ung","doi":"10.1016/j.cllc.2025.03.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The follow-up of patients with lung cancer after curative-intent treatment should include strategies to improve their quality of life and survival. These could include the monitoring and management of symptoms of recurrence and late toxicities from cancer treatments, the use of patient-reported outcome (PRO) tools, and smoking cessation interventions. The objective of this systematic review was to examine these follow-up strategies.</p><p><strong>Materials and methods: </strong>This systematic review was developed by Ontario Health (Cancer Care Ontario)'s Program in Evidence-Based Care. MEDLINE, EMBASE, and the Cochrane Library were searched for systematic reviews and randomized controlled trials (RCTs) comparing different types of clinicians, PRO tools, smoking cessation interventions, and management strategies for signs, symptoms, risk factors, comorbidities, or late toxicities in adult patients with NSCLC or SCLC after curative-intent treatment.</p><p><strong>Results: </strong>Thirty-five RCTs and nineteen systematic reviews were included. For nurse-led interventions, either significant effects were found in favor of the intervention, or no significant effects were found. The results for the use of PRO tools were mixed, possibly due to differences in comparators and settings. Evidence suggested that smoking cessation interventions might benefit these patients (RR, 0.84; 95% CI, 0.68-1.03). There was limited evidence in the target population for the management of signs, symptoms, risk factors, comorbidities, or late toxicities.</p><p><strong>Conclusions: </strong>Smoking cessation interventions, exercise training, and the use of PRO tools may benefit these patients. The results of this systematic review were used to inform recommendations in a clinical practice guideline. Further RCTs in this patient population are needed.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer.\",\"authors\":\"Yaron Shargall, Emily T Vella, Maria Elisabeth Del Giudice, Carole Dennie, Peter M Ellis, Swati Kulkarni, Robert MacRae, Yee C Ung\",\"doi\":\"10.1016/j.cllc.2025.03.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The follow-up of patients with lung cancer after curative-intent treatment should include strategies to improve their quality of life and survival. These could include the monitoring and management of symptoms of recurrence and late toxicities from cancer treatments, the use of patient-reported outcome (PRO) tools, and smoking cessation interventions. The objective of this systematic review was to examine these follow-up strategies.</p><p><strong>Materials and methods: </strong>This systematic review was developed by Ontario Health (Cancer Care Ontario)'s Program in Evidence-Based Care. MEDLINE, EMBASE, and the Cochrane Library were searched for systematic reviews and randomized controlled trials (RCTs) comparing different types of clinicians, PRO tools, smoking cessation interventions, and management strategies for signs, symptoms, risk factors, comorbidities, or late toxicities in adult patients with NSCLC or SCLC after curative-intent treatment.</p><p><strong>Results: </strong>Thirty-five RCTs and nineteen systematic reviews were included. For nurse-led interventions, either significant effects were found in favor of the intervention, or no significant effects were found. The results for the use of PRO tools were mixed, possibly due to differences in comparators and settings. Evidence suggested that smoking cessation interventions might benefit these patients (RR, 0.84; 95% CI, 0.68-1.03). There was limited evidence in the target population for the management of signs, symptoms, risk factors, comorbidities, or late toxicities.</p><p><strong>Conclusions: </strong>Smoking cessation interventions, exercise training, and the use of PRO tools may benefit these patients. The results of this systematic review were used to inform recommendations in a clinical practice guideline. Further RCTs in this patient population are needed.</p>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cllc.2025.03.003\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cllc.2025.03.003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Systematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer.
Introduction: The follow-up of patients with lung cancer after curative-intent treatment should include strategies to improve their quality of life and survival. These could include the monitoring and management of symptoms of recurrence and late toxicities from cancer treatments, the use of patient-reported outcome (PRO) tools, and smoking cessation interventions. The objective of this systematic review was to examine these follow-up strategies.
Materials and methods: This systematic review was developed by Ontario Health (Cancer Care Ontario)'s Program in Evidence-Based Care. MEDLINE, EMBASE, and the Cochrane Library were searched for systematic reviews and randomized controlled trials (RCTs) comparing different types of clinicians, PRO tools, smoking cessation interventions, and management strategies for signs, symptoms, risk factors, comorbidities, or late toxicities in adult patients with NSCLC or SCLC after curative-intent treatment.
Results: Thirty-five RCTs and nineteen systematic reviews were included. For nurse-led interventions, either significant effects were found in favor of the intervention, or no significant effects were found. The results for the use of PRO tools were mixed, possibly due to differences in comparators and settings. Evidence suggested that smoking cessation interventions might benefit these patients (RR, 0.84; 95% CI, 0.68-1.03). There was limited evidence in the target population for the management of signs, symptoms, risk factors, comorbidities, or late toxicities.
Conclusions: Smoking cessation interventions, exercise training, and the use of PRO tools may benefit these patients. The results of this systematic review were used to inform recommendations in a clinical practice guideline. Further RCTs in this patient population are needed.
期刊介绍:
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.